Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study (CCCA)
Central Centrifugal Cicatricial Alopecia (CCCA)
About this trial
This is an interventional treatment trial for Central Centrifugal Cicatricial Alopecia (CCCA) focused on measuring alopecia, Hair loss, Female hair loss, Minoxidil, Topical Steroid
Eligibility Criteria
Inclusion Criteria:
- African-American women, ages 18-60 years old
- with a clinical diagnosis and biopsy-proven CCCA, with Central Scalp Alopecia Scale severity 1 through 4 will be included in this study
- These subjects will be seen and treated in Wake Forest Baptist Health Dermatology Outpatient Clinic
Exclusion Criteria:
- Patients with other forms of hair loss in addition to CCCA will be excluded
- Other patients to be excluded are those with other forms of inflammatory scalp disease (with the exception of mild seborrheic dermatitis)
- patients who have had topical treatment for CCCA within the past 4 months (including topical steroids, topical minoxidil, or any other topical hair regrowth medication)
- patients who have been on a long-term oral antibiotics for hair loss within the past year
- patients who have undergone more than two rounds of intralesional steroid injections to the scalp in the past one year.
Sites / Locations
- Wake Forest Baptist Health Department of DermatologyRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Topical steroid plus oral antibiotic group
Topical steroid plus intralesional steroid injection group
Participants in this group receive topical steroid (class I-II applied once daily) plus oral antibiotic group (doxycyline 100 mg twice daily for 6 months), and then topical minoxidil (5% solution or foam) after 8 months of treatment.
Participants in this group receive topical steroid (class I-II applied once daily) plus intralesional steroid group (7.5mg/cc of kenaolog, max dose of 3 cc), and then topical minoxidil (5% solution or foam) after 8 months of treatment